Table 4.
Demographics, immunosuppressives and treatment regimens of vaccinated death patients.
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
|---|---|---|---|---|
| Sex | Female | Female | Female | Female |
| Age (years) | 52 | 49 | 60 | 46 |
| Etiology of CKD | Unknown | Diabetic nephropathy | Polycystic kidney disease | Polycystic kidney disease |
| Type of donor | Cadaver | Living | Living | Living |
| Induction regimen | ATLG | ATLG | ATLG | ATLG |
| Maintenance IS | Tac + MMF + Steroid | Tac + MMF + Steroid | Tac + MMF + Steroid | Tac + MMF + Steroid |
| Time from Tx to COVID-19 (months) | 49 | 143 | 182 | 74 |
| Doses of vaccination | Two doses | Two doses | Three doses | Two doses |
| Type of vaccines | CoronaVac | CoronaVac | Two CoronaVac and one BNT162b2 |
BNT162b2 |
| Time from the last vaccine to hospitalization (days) | 92 | 33 | 45 | 57 |
| Length of hospitalization (days) | 15 | 21 | 22 | 11 |
| Severity of COVID-19 | Critically severe | Critically severe | Critically severe | Critically severe |
| Cytokine storm | Yes | Yes | Yes | Yes |
|
Changes of IS during COVID-19 |
Withdrawal of TAC + MMF | Withdrawal of TAC + MMF | Withdrawal of TAC + MMF | Withdrawal of TAC + MMF |
| Antiviral agents | Favipiravir | Favipiravir | Favipiravir | Favipiravir |
| Anticoagulation | Enoxaparin | Enoxaparin | Enoxaparin | Enoxaparin |
Abbreviations; TAC: Tacrolimus; MMF: Mycophenolate mofetil.